ESR2 and neoplasm: The expression of ERβ declines during tumor progression (34, 60), and analysis of clinical samples provided initial evidence that the reduced expression of ERβ could relate to tumor stage and grade, and to other characteristics of poor prognosis (including poorly differentiated tissue, vascular invasion, and decreased apoptotic index) (32, 33, 36).